Enzyme News and Research

RSS

Experts to focus on Shwachman-Diamond Syndrome at New York Academy of Sciences conference

On June 28-30, 2011, the New York Academy of Sciences will bring together scientists and clinicians from a wide range of subspecialties, in addition to patients and caregivers, to discuss the most important recent advances in our understanding of the clinical features, management, and treatment of Shwachman-Diamond Syndrome (SDS)-a rare disorder involving multiple organ systems and affecting children and young adults.

23 Jun 2011

Two NJIT researchers receive U.S. Patent for nanoprobe array technique

Reginald C. Farrow and Zafer Iqbal, research professors at NJIT, were awarded a patent today for an improved method of fabricating arrays of nanoscale electrical probes. Their discovery may lead to improved diagnostic tools for measuring the spatial variation of electrical activity inside biological cells.

22 Jun 2011

CEL-SCI announces results from Multikine Phase II trial on head and neck cancer

CEL-SCI Corporation announced today data from its Phase II clinical studies which showed that its lead drug Multikine was able to lower cholesterol in studies involving 120 head and neck cancer patients.

22 Jun 2011

Atrium to focus on metabolic syndrome, nutrition research

Atrium Innovations Inc., a recognized leading developer, manufacturer and marketer of professionally endorsed, science-based dietary supplements for the health and nutrition industry, today announced a multi-year commitment to nutrition research and to a comprehensive program focusing on metabolic syndrome.

21 Jun 2011

University of Virginia professor speaks about gender disparity in abdominal aortic aneurysms

At the 65th Vascular Annual Meeting of the Society for Vascular Surgery, Gilbert R. Upchurch, Jr., MD from the division of thoracic and cardiovascular surgery at University of Virginia Health System in Charlottesville, spoke about gender differences in abdominal aortic aneurysms.

18 Jun 2011

Cervical ripening that instigates preterm birth is distinct from normal term labor

Cervical ripening that instigates preterm labor is distinct from what happens at the onset of normal term labor, researchers at UT Southwestern Medical Center have found.

18 Jun 2011

Sunshine enters Adva-27a cancer research and development agreement with The Jewish General Hospital

Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Jewish General Hospital, one of McGill University's Hospital Centers, to conduct the necessary research and development to advance Sunshine's lead compound, Adva-27a, through the various stages of preclinical studies and Phase I clinical trials.

17 Jun 2011

UCLA researchers find new potential therapeutic target for preventing HIV

Specific types of "helper" T cells that are crucial to maintaining functioning immune systems contain an enzyme called PDI. This enzyme affects how proteins fold into specific shapes, which in turn influences how the T cells behave.

16 Jun 2011

Healthy diet, antioxidants, critical nutrients and activities may provide the foundation to youthful living

As the baby boomer generation continues to increase in age, so does its passion to remain youthful, both inside and out. Beating the clock is now a multi-faceted, science-driven industry. From its age-old quests to find the elixir of life, to modern exploration of how microcellular activity contributes to metabolic breakdown, scientific research continues to advance its goals to enhance bodily energy, vigour and performance, and fade or stall the visible signs of aging.

16 Jun 2011

Magnesium essential for absorption and metabolism of vitamin D and calcium

Magnesium deficiency is an important factor in the results obtained from vitamin D. According to Dr. Carolyn Dean, MD, ND, magnesium expert and Medical Director of the nonprofit Nutritional Magnesium Association, the effectiveness and benefits of vitamin D are greatly undermined in the absence of adequate levels of magnesium in the body.

15 Jun 2011

Overactive mTOR can result in serious disruption of kidney filter in diabetes patients

Diabetes mellitus is one of the most common secondary diseases in modern society. And because it is on the rise, it is also one of the greatest challenges facing medicine today. Diabetes patients do not die as a direct result of the increase in blood sugar, but from the long-term complications of their disease, in which the increase in blood sugar causes damage to blood vessels and organs.

15 Jun 2011

Jamieson introduces UC-II undenatured collagen to relieve osteoarthritis pain

Most people think that arthritis is an inevitable part of aging. Today, Jamieson Laboratories has introduced UC-II undenatured collagen, a formulation that will turn back the clock on joint pain by naturally promoting the restoration of cartilage and inhibiting its deterioration. This new anti-aging formula taken only once daily is proven to be twice as effective as other joint remedies.

15 Jun 2011

Study links cysteine with obesity-related diseases

People with high levels of the amino acid cysteine carry 6-10 kilograms more fat than other people. Norwegian researchers studying this phenomenon are generating knowledge which could help to prevent and treat life-threatening obesity.

15 Jun 2011

FDA approves Abbott's CREON capsules for treatment of EPI due to cystic fibrosis

Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON Delayed-Release Capsules to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis.

15 Jun 2011

Abbott’s CREON receives FDA approval for infant-specific dose

Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON® (pancrelipase) Delayed-Release Capsules to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF). The CREON 3,000 units of lipase capsule provides the lowest dosage strength in the class approved by the FDA. This new option will enable more precise dosing titration in accordance with the Cystic Fibrosis Foundation guidelines for infant dosing.

14 Jun 2011

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

New findings from a multi-center, randomized, placebo-controlled clinical study of Deplin 15mg added to commonly prescribed antidepressants known as selective serotonin reuptake inhibitors showed that all patients who achieved remission at 30 days using Deplin 15mg adjuvant therapy, and who chose to enter a 12 month maintenance phase, maintained their remission after a year of treatment.

14 Jun 2011

Scientists discover new elements of blood clot-formation process

Scripps Research Institute scientists have discovered new elements of the blood clot-formation process. The findings could lead to better drugs for preventing heart attacks and other clot-related conditions.

14 Jun 2011

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.

13 Jun 2011

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced an exclusive worldwide licensing agreement that will add two distinct nucleotide analogues to Vertex's hepatitis C portfolio.

13 Jun 2011

Trimeris, Synageva enter definitive merger agreement

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, and Trimeris, Inc., announced today that they have entered into a definitive agreement under which Synageva will merge with Trimeris in an all-stock transaction.

13 Jun 2011

Enzyme News and Research

Experts to focus on Shwachman-Diamond Syndrome at New York Academy of Sciences conference

Two NJIT researchers receive U.S. Patent for nanoprobe array technique

CEL-SCI announces results from Multikine Phase II trial on head and neck cancer

Atrium to focus on metabolic syndrome, nutrition research

University of Virginia professor speaks about gender disparity in abdominal aortic aneurysms

Cervical ripening that instigates preterm birth is distinct from normal term labor

Sunshine enters Adva-27a cancer research and development agreement with The Jewish General Hospital

UCLA researchers find new potential therapeutic target for preventing HIV

Healthy diet, antioxidants, critical nutrients and activities may provide the foundation to youthful living

Magnesium essential for absorption and metabolism of vitamin D and calcium

Overactive mTOR can result in serious disruption of kidney filter in diabetes patients

Jamieson introduces UC-II undenatured collagen to relieve osteoarthritis pain

Study links cysteine with obesity-related diseases

FDA approves Abbott's CREON capsules for treatment of EPI due to cystic fibrosis

Abbott’s CREON receives FDA approval for infant-specific dose

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

Scientists discover new elements of blood clot-formation process

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Trimeris, Synageva enter definitive merger agreement

Understanding the DNA Damage Response in Innate Immunity eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo